PDL BioPharma, Inc.
PDLIV
NASDAQ
Recommendation
Prev Close
--
Volume
--
Avg Vol (90D)
--
Market Cap
--
Dividend & Yield
--
52-Week Range
-- - --
P/E (TTM)
--
EPS (TTM)
| 08/31/2020 | 06/30/2020 | 03/31/2020 | 12/31/2019 | 09/30/2019 | |
|---|---|---|---|---|---|
| Net Income | -- | -49.97M | -31.72M | -54.89M | -17.78M |
| Total Depreciation and Amortization | -- | 878.00K | 996.00K | 1.06M | 1.12M |
| Total Amortization of Deferred Charges | -- | 205.00K | 280.00K | 1.46M | 1.90M |
| Total Other Non-Cash Items | -- | 41.46M | 28.61M | 38.07M | 2.45M |
| Change in Net Operating Assets | -- | -5.64M | -17.18M | -4.85M | 7.19M |
| Cash from Operations | -- | -13.06M | -19.02M | -19.15M | -5.12M |
| Capital Expenditure | -- | -142.00K | -93.00K | -259.00K | -341.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 11.40M | 13.57M | 20.98M | 30.56M |
| Cash from Investing | -- | 11.26M | 13.48M | 20.72M | 30.22M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00 | -18.85M | -97.89M | -7.45M |
| Issuance of Common Stock | -- | 461.00K | -- | -- | -- |
| Repurchase of Common Stock | -- | -20.15M | -19.23M | -11.01M | -4.63M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -9.00K | -- |
| Other Financing Activities | -- | 0.00 | -3.02M | 6.51M | -3.69M |
| Cash from Financing | -- | -19.69M | -41.09M | -102.40M | -15.77M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -21.50M | -46.63M | -100.82M | 9.33M |